探索肝硬化:对治疗策略进步的见解
Magdalena Wiacek1, Anna Adam1, Rafał Studnicki2
1Department of Medical and Health Sciences, Radom University, Chrobrego 27, 26-600 Radom, Poland.
肝硬化是死亡的主要原因,是由代谢功能障碍驱动的. 针对关键途径的新疗法为逆转肝纤维化和改善患者存活率提供了希望.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 代谢综合征是代谢综合征的一种.
- 分子生物学分子生物学
背景情况:
- 肝硬化是一个重要的全球健康问题,死亡率很高.
- 由于病毒性肝炎,滥用酒精和代谢综合征,患病率正在平稳.
- 目前的治疗方法在逆转已经确定的肝纤维化方面往往是无效的.
研究的目的:
- 合成肝硬化的多因素驱动因素.
- 强调代谢功能障碍在疾病进展中的作用.
- 审查新兴的肝硬化治疗分子策略.
主要方法:
- 文献综述合成了肝硬化多因素驱动因素.
- 关注新陈代谢功能障碍:线粒体功能障碍,新陈代谢改变,炎症.
- 分析新兴的分子和细胞治疗策略.
主要成果:
- 代谢功能障碍,包括线粒体损伤和炎症,是肝硬化进展的核心原因.
- 已经确定的纤维化很难用当前的治疗方法逆转.
- 新兴疗法针对AMPK,FGF21和线粒体功能等关键病原性途径.
结论:
- 代谢功能障碍显著加剧了肝硬化.
- 新型分子策略在向纤维生成和恢复肝脏平衡方面表现有前途.
- 整合系统生物学的精准医学方法对于未来的干预至关重要.
更多相关视频
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
相关概念视频
Chronic Pancreatitis II: Collaborative Care
Assessment:
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Heart Failure VI: Adjunct Therapies
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
